EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanoparticles coated with immune cell hybrid membranes for targeted delivery of janus kinase inhibitors and synergistic treatment of autoimmune myocarditis

Zhenhao Zhang, Yulong Xiong, Shangyu Liu, Lishui Shen, Lihui Zheng, Ligang Ding, Lingmin Wu, Limin Liu, Minghao Zhao, Le Li, Zhuxin Zhang, Sheng Su und 4 weitere

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.09.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Zhenhao Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Acade…. Hauptthemen laut MEDLINE: Myocarditis, Autoimmune Diseases, Nanoparticles, Sulfonamides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune myocarditis is a complicated, inflammatory heart disease with high morbidity and mortality. Interferon (IFN)-γ-mediated classical activated macrophage (M1 macrophage) polarization and pyroptosis play a vital role in immune injury in myocarditis. Baricitinib, a selective Janus kinase (JAK) 1 and JAK2 inhibitor, has been used in the treatment of some systemic autoimmune diseases to effectively suppress pro-inflammatory macrophages by blocking the JAK2-signal transducer and activator of transcription 1 (STAT1) signaling pathway. Nevertheless, its application to autoimmune myocarditis was hindered due to the difficulty of delivering and accumulating the drug in heart tissue. To overcome these limitations, we synthesized a hybrid membrane containing CC motif chemokine receptor (CCR) 1 and CXC motif chemokine receptor (CXCR) 3 from activated RAW264.7 and EL4 cell lines to target inflammatory lesions. Furthermore, mesoporous polydopamine (MPDA) was employed due to its synergistic effects, including high drug loading efficiency, reactive oxygen species (ROS) adsorption, and dual responsiveness to glutathione (GSH) and pH, to fabricate RAW-EL4 hybrid membrane-coated Baricitinib-MPDA nanoparticles (BM@[RAW-EL4] NPs) for Baricitinib delivery. Subsequent in vitro and in vivo experiments verified that BM@[RAW-EL4] NPs significantly inhibited inflammatory infiltration and heart tissue injury by precisely suppressing macrophage polarization and pyroptosis. Biotoxicity and biosafety tests also revealed the biocompatibility of BM@[RAW-EL4] NPs, which provided the foundation for further clinical translation. Hence, the biomimetic BM@[RAW-EL4] NPs offer new heart-specific delivery opportunities, representing a versatile platform for targeted therapy in autoimmune myocarditis. STATEMENT OF SIGNIFICANCE: Autoimmune myocarditis is defined as an intense immune injury in the heart tissue, with current treatment far from satisfactory. IFN-γ-mediated M1 macrophage polarization and pyroptosis are crucial to disease progression. In this study, we created RAW-EL4 hybrid membrane-coated Baricitinib-MPDA nanoparticles (BM@[RAW-EL4] NPs) to achieve targeted delivery of an IFN-γ inhibitor to the inflammatory site. RAW-EL4 hybrid membranes endowed the nanomedicine with chemotactic property under the mechanism of activated CCR1-CCL7/8 and CXCR3-CXCL9/10 axis. MPDA exhibited a high drug-loading efficiency of 49.0 % and dual responsiveness to GSH and pH. We also observed its ability to clear ROS in the study. These characteristics of MPDA promoted the release of Baricitinib and macrophage suppression. In vivo experiments revealed the therapeutic effect and biosafety of BM@[RAW-EL4] NPs for the potential application to autoimmune myocarditis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisAutoimmune DiseasesNanoparticlesSulfonamidesJanus Kinase InhibitorsPyrazolesAzetidinesMembranes, ArtificialDrug Delivery SystemsAnimalsMicePurinesRAW 264.7 CellsMaleIndolesMacrophagesPolymersMice, Inbred BALB C

Stichwörter der Autor:innen

Autoimmune myocarditisCell membrane-coated nanoparticlesJAK inhibitorsMacrophage polarization and pyroptosisMesoporous polydopamine

Substanzen

baricitinibSulfonamidesPurinesJanus Kinase InhibitorsPyrazolesAzetidinesIndolespolydopamineMembranes, ArtificialPolymers

Autor:innen und Institutionen

  • Department of Cardiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167A Beilishi…

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, Z., Xiong, Y., Liu, S., Shen, L., Zheng, L., Ding, L., Wu, L., Liu, L., Zhao, M., Li, L., Zhang, Z., Su, S., Peng, X., Zhou, L., Xu, M., & Yao, Y. (2025). Nanoparticles coated with immune cell hybrid membranes for targeted delivery of janus kinase inhibitors and synergistic treatment of autoimmune myocarditis. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.09.013

Vancouver

Zhang Z, Xiong Y, Liu S, Shen L, Zheng L, Ding L, et al. Nanoparticles coated with immune cell hybrid membranes for targeted delivery of janus kinase inhibitors and synergistic treatment of autoimmune myocarditis. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.09.013

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhenhao and Xiong, Yulong and Liu, Shangyu and Shen, Lishui and Zheng, Lihui and Ding, Ligang and Wu, Lingmin and Liu, Limin and Zhao, Minghao and Li, Le and Zhang, Zhuxin and Su, Sheng and Peng, Xi and Zhou, Likun and Xu, Mengtong and Yao, Yan},
  title = {Nanoparticles coated with immune cell hybrid membranes for targeted delivery of janus kinase inhibitors and synergistic treatment of autoimmune myocarditis},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.09.013}
}
Kostenlos starten →